Protagonist Therapeutics, Inc (PTGX)

Pharmaceutical Preparations · market cap $9.1B · as of 2026-07-12

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Protagonist Therapeutics (PTGX) is a clinical-stage pharmaceutical company with a market cap of ~$8.45B and a lead asset PTG-300 in Phase 2 for Polycythemia Vera (PV). The stock trades at ~$131.42, well above the analyst consensus price target of ~$118.69, implying the market is pricing in significant upside beyond current sell-side estimates. Cash of $193.7M provides roughly 12 months of runway, creating a near-term financing overhang.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
PTG-300	Phase 2	Polycythemia Vera

Price & technical context

3-month

+6.7%

6-month

+35.2%

12-month

+119.2%

52-wk range

$64.14–$158.62

vs 50-day MA

-3.2%

vs 200-day MA

+26.1%

Realized vol

47.8%

Max drawdown

-31.6%

Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for PTGX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.